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Ulf-Håkan Stenmanb and Harri Visap€a€aa,c
aDepartment of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; bDepartment of Clinical Chemistry,
University of Helsinki and Helsinki University Hospital, Helsinki, Finland; cDepartment of Oncology, University of Helsinki and Helsinki
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ABSTRACT
Objective: Tumour associated trypsin inhibitor (TATI) is a peptide that is a marker for several tumours.
TATI may also behave as an acute phase reactant in severe inflammatory disease. Overexpression of TATI
predicts an unfavourable outcome for many cancers. This study aimed to evaluate the prognostic value of
pre- and postoperative concentration of TATI in serum (S-TATI) of patients with renal cell carcinoma (RCC).
Materials and methods: S-TATI was determined by time resolved immunofluorometric assay in pre-
operative and postoperative samples that were collected from 132 RCC patients, who underwent par-
tial or complete nephrectomy in Helsinki University Hospital from May 2005 to July 2010.
Results: Preoperative S-TATI was significantly associated with tumour stage, lymph-node involvement,
metastatic stage, Chronic Kidney Disease Stage (CKD grade), and preoperative C-reactive protein level
(p< 0.05). Postoperative S-TATI was significantly associated only with CKD grade (p< 0.001).
Multivariate Cox regression analysis of postoperative S-TATI, as a continuous variable, was an inde-
pendent prognostic factor for overall survival (HR¼ 1.01, 95% CI¼ 1.001.01, p¼ 0.03) and cancer-spe-
cific survival (CSS) (HR¼ 1.01, 95% CI¼ 1.001.02, p¼ 0.004).
Conclusions: Our data suggest that elevated postoperative S-TATI may be associated with adverse
prognosis in RCC patients.
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Introduction
Renal cell carcinoma (RCC) is the most lethal urological
malignancy. Merely 49% of all RCC patients survive beyond 5
years [1]. To decide who benefits from nephrectomy or more
complication-prone partial nephrectomy, there is a need to
estimate the survival of each patient. The postoperative fol-
low-up for local RCCs aims to find these 20–40% of RCC
patients, operated on for curative intention, whose disease
recur [2]. Abundance of prognostic nomograms combining
laboratory parameters, clinical, anatomical and histopatho-
logical features exist to predict the likelihood of progression
or mortality of patients with local and advanced RCC [3,4].
Despite the surge for optimum prognostic markers, the esti-
mates of survival and recurrence still rely on the Tumor,
Node, Metastasis (TNM) classification, being the most robust
predictor of adverse oncological outcomes. Currently, no
serum biomarker for RCC is recommended for routine diag-
nostic or monitoring use in clinic [5].
Tumour-associated trypsin inhibitor (TATI), also called ser-
ine peptidase inhibitor Kazal-type 1 (SPINK1) or pancreatic
secretory trypsin inhibitor (PSTI), was identified in the urine
of an ovarian cancer patient [6]. A single gene on chromo-
some 5, SPINK1, encodes TATI [7].
The reference values for serum of TATI (S-TATI) in a
healthy adult were 3–16 mg/l, corresponding to 0.5–2.6 nmol/l
[7]. A cut-off of 16 mg/l has been shown to be a useful
threshold for predicting a prognosis in patients with RCC
[8,9]. S-TATI may be elevated in patients with various malig-
nancies. S-TATI may also be elevated by reduced kidney
function (GFR < 60ml/min) [7,10,11] and by severe inflam-
matory diseases [12,13].
S-TATI seems to predict survival in several cancers
[7,14–16]. An increase in S-TATI levels after radically intended
surgery of ovarian cancer predicts the recurrence and occur-
rence of metastases [16]. A recent study by Peltonen et al.
[15] reported that S-TATI, taken at 3 months after resection
of liver metastasis of colorectal carcinoma, was not associ-
ated with shorter disease-free survival or overall survival (OS).
Preoperatively elevated S-TATI determinations have been
shown to predict shorter survival in patients with RCC [8].
The prognostic value of postoperative S-TATI of RCC patients,
however, has not been studied.
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Preoperative and postoperative identification of patients
at high risk of cancer recurrence is of paramount importance
for choosing the optimal follow-up protocol and adjuvant
treatment [17]. In the present study, we evaluated the prog-
nostic significance of preoperative and postoperative serum
concentration of TATI in patients with RCC.
Materials and methods
Patient data
After we received institutional review board approval (The
Ethics Committee of Helsinki University hospital, permission
number 8/28/1/2004), patients that had been diagnosed with
a radiological mass suspected to be a renal tumour and
scheduled to be operated on in Helsinki University Hospital
(HUCH) from May 2005 to July 2010 were asked to partici-
pate in the study. Patients with a renal tumour and who had
provided their written informed consent were included in
the study. No exclusions based on patient or tumour ana-
tomical characteristics were applied at the time of recruit-
ment. Serum samples were collected from 173 patients
before and at a minimum of 3weeks after the operation.
Patients, whose final pathology was benign or non-RCC can-
cer, were excluded. As described before by Tramonti et al.
[10,11], increased S-TATI values have been associated with
reduced kidney function. After confirming the correlation
between Chronic Kidney Disease Stage (CKD) grades and S-
TATI, five patients (4%) with CKD grade 4 and three patients
(2%) with CKD grade 5 postoperatively were excluded from
the analysis of postoperative samples. Moreover, patients
with severely reduced renal function preoperatively (CKD
grade > 4) were excluded from analysis of preoperative sam-
ples. None of the patients had acute pancreatitis or any
acute infection at the time of TATI measurement. After these
exclusions, a total of 132 patients treated with radical or par-
tial nephrectomy for RCC were included in the study-group
(Figure 1).
Histology was based on the WHO 2004 classification [18]
and the tumors were staged according to the TNM 2009
classification [19]. For statistical analyses, the Fuhrman grade
was dichotomized (grades 12 and 34 combined) as some
studies indicate the Fuhrman grading system to be a better
prognostic factor when grouped [20]. The T-stage was corres-
pondingly dichotomized into local T-stages (T-stage 12)
and locally advanced stages (34). Preoperative assessment
of metastatic status was based on computed tomography of
the thorax, abdomen, and pelvis. Pathological lymph node
status was evaluated either radiologically or confirmed
pathologically by lymphadenectomy.
Patients were followed at the HUCH outpatient depart-
ment with routine follow-up that included CT and MRI imag-
ing at 6–12-month intervals. Information on disease
progression, survival, and official cause of death certificates
up to June 2017 were obtained from the HUCH patient regis-
try and Statistics Finland. No patients were lost to follow-up.
Blood samples and serum assay protocols
Blood samples for serum analyses were drawn at a median
of 1.0 day (range¼ 050 days) prior to and at a median of
52 days (range¼ 25176 days) after surgery. Serum was
stored at 20 C before assay of S-TATI by time-resolved
immunofluorometry (TR-IFMA), as previously described [21].
Statistical analyses
Statistical analyses were performed using SPSSVR Statistics
software (Version 24; IBM Corp., Armonk, NY). The S-TATI
concentrations in patients with various disease stages and
grades were non-normally distributed, therefore they were
analyzed by non-parametric tests. Correlations between S-
TATI, as a continuous variable, and clinical parameters were
calculated using Spearman’s rho, Mann-Whitney U-test and
Kruskal-Wallis test when appropriate. Differences in median
pre- and postoperative TATI measurements were analysed
using the Wilcoxon signed-rank test.
Cancer-specific survival (CSS), OS and disease recurrence were
analysed by the Kaplan-Meier method. Statistically significant
covariates in univariate analysis (UVA) were also studied by multi-
variate analysis (MVA) with the Cox proportional hazards model. A
two-sided p< 0.050 was considered statistically significant.
Results
Patient and clinical characteristics
The clinical characteristics of the patients at the time of diag-
nosis are presented in Table 1. The median age was 64 years
(range¼ 2487). Eighteen patients (14%) underwent partial
nephrectomy and 114 (86%) radical nephrectomy. Fifty-eight
patients (44%) had local disease (T1aT2c) and 74 (56%)
locally advanced disease (T3aT4). Fourteen (11%) had
lymph node involvement and 25 (19%) had metastatic dis-
ease. A majority of the patients (n¼ 114, 86%) had clear-cell
renal cell carcinoma (ccRCC).Figure 1. Flowchart showing exclusions and study population.
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The median concentration of S-TATI was 13.0 mg/l pre-
operatively (interquartile range (IQR)¼ 9.919.5) and 18.3 mg/
l postoperatively (IQR¼ 13.624.3) for all patients (Wilcoxon
signed-rank test, Z¼5.70, p< 0.001). Postoperative median
S-TATI value was 16.9 mg/l (IQR¼ 13.523.2) for patients who
underwent tumour excision with radical intent.
Based on ROC analysis the optimal cut-off is 16.5mg/l. The
AUC value for prediction of OS was 0.633 for S-TATI (p¼ 0.01)
and 0.655 for P-CRP (p< 0.001) for all patients (Figure 2).
As a continuous variable, preoperative S-TATI was signifi-
cantly associated with T-stage (p¼ 0.001), lymph-node involve-
ment (p¼ 0.04), metastatic stage (p¼ 0.04), CKD grade
(p< 0.001) and preoperative CRP level (p¼ 0.01), but not with
Fuhrman grade (p¼ 0.08). Preoperative S-TATI was not signifi-
cantly associated with malignancy (p¼ 0.08). The distribution
of preoperative S-TATI measurements in benign and malig-
nant diseases are presented in Figure 3. Postoperative S-TATI
was associated significantly only with CKD grade (p< 0.001).
Median serum creatinine concentration was 78mmol/l
(IQR¼ 6490) preoperatively and 105mmol/l (IQR¼ 91125)
postoperatively. As a continuous variable, postoperative S-TATI
concentrations correlated with CKD grade (rho¼ 0.52, p< 0.001)
better than with glomerular filtration rate (GFR) (rho¼ 0.50,
p< 0.001) or creatinine concentration (rho¼ 0.37, p< 0.001).
Survival analysis
The median follow-up time after operation was 84months
(range¼ 3153months) for the whole study group and
97months (range¼ 5153months) for N0M0 patients. At the
end of the follow-up, 55 patients (41.4%) were alive and 78
(58.6%) were dead. Forty-one patients (53%) died of RCC and
37 (47%) of other causes.
UVA and MVA of OS expressed as hazard ratios and TATI
as a continuous variable are presented in Table 2. For OS,
patient age, N-stage, M stage, T stage and postoperative S-
TATI were significant in UVA. In MVA, postoperative S-TATI
remained significant along with age, lymph-node involve-
ment and metastatic state.
For CSS postoperative S-TATI, N-stage, M-stage and T-
stage were statistically significant for UVA. In MVA, postoper-
ative S-TATI remained significant along with N-stage, M-stage
and T-stage (Table 3).
As a dichotomized variable with a cut-off > 16mg/l, postoper-
ative S-TATI was also a statistically significant predictor of OS in
Kaplan-Meier survival analysis (log-rank test p¼ 0.02) (Figure 4)
and in Cox univariate logistic regression (HR¼ 1.83, 95%
CI¼ 1.123.00, p¼ 0.02). In MVA, only age (HR¼ 1.03,
95% CI¼ 1.011.05, p¼ 0.007), N-stage (HR¼ 3.29, 95%
CI¼ 1.632.35, p¼ 0.001) and M-stage (HR¼ 2.48, 95%
CI¼ 1.344.60, p¼ 0.004) remained significant predictors for OS.
With a cut-off of 16mg/l, the preoperative concentration
of S-TATI was also shown to predict both CSS and OS in
Kaplan-Meier (p¼ 0.04 for CSS and p¼ 0.02 for OS) (Figure 5)
and Cox UVA (HR¼ 1.91, 95% CI¼ 1.043.52, p¼ 0.04 for
CSS and HR¼ 1.71, 95% CI¼ 1.092.69, p¼ 0.02 for OS).
Furthermore, the Cox proportional hazards model was run
with no exclusions based on kidney dysfunction (n¼ 140).
The postoperative S-TATI was able to predict CSS signifi-
cantly both in univariate analysis with COX proportional haz-
ards model (p¼ 0.026, HR¼ 1.007, 95% CI¼ 1.001–1.014) and
in multivariate analysis (p¼ 0.007) together with N-stage
(p¼ 0.001), M-stage (0.001) and T-stage (p¼ 0.01). Without
exclusions for kidney dysfunction, postoperative S-TATI failed
to predict OS significantly.
Disease recurrence
Of 101 patients operated on with radical intention, 26 (26%)
had disease recurrence during follow-up. The histological
Figure 2. ROC curve analysis. ROC curve analysis of S-TATI and P-CRP for over-
all mortality of RCC patients.
Table 1. Table of demographic and histological features of patients
and tumours.
n %
Number of eligible patients 132
Age, median (range) 64 24-87 years
Sex
Men 62 47
Women 70 53
Histology
Clear cell renal carcinoma (ccRCC) 114 86
Papillary renal carcinoma 15 11
Chromophobe carcinoma 1 0,8
Other renal malignancy
Nephroblastoma 1 0,8
Carcinoma of the collecting duct 1 0,8
T-stage
stage T1T2 58 44
stage T3T4 74 56
N-stage
N0 118 89
N1 14 11
M-stage
M0 107 81
M1 25 19
Fuhrman Grade
grade 12 64 48
grade 34 63 48
Missing values 5 4
Operation type
Partial nephrectomy 18 14
Radical nephrectomy 114 86
ccRCC Patients N0M0 at the time of diagnosis
Number of eligible patients 88
No recurrence 62 71
Disease recurrence 26 29
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subtype of these was ccRCC. Recurring patients had a
median postoperative S-TATI of 18.3mg/l (IQR¼
14.520.2 mg/l). The median follow-up time to recurrence
was 13months (range¼ 2112months). A postoperative S-
TATI cut-off limit of 16 mg/l did not significantly predict recur-
rence (p¼ 0.2) in patients with ccRCC.
Figure 3. Distribution of S-TATI according to disease. Box plots displaying s-TATI distribution according to malignancy (a), tumour stage (b), nodal stage (c) and
metastatic stage (d). Boxes show 25th, 50th and 75th percentiles, whiskers show 5th and 95th percentiles. Outliers are represented with circles while black stars
represent extreme outliers. Figure (a) includes benign tumours, but other figures include only malignant tumours.
Table 2. Univariate and multivariate analyses of postoperative S-TATI, other prognostic factors and RCC overall survival.
UVA MVA
Variable Patients (n) HR 95% CI p HR 95% CI p
Sex
Female 62
Male 70 0.72 0.461.13 0.15
Patient age (years) 132 1.03 1.011.05 0.01 1.03 1.011,01 0.004
Postoperative s-TATI as continuous variable 132 1.01 1.001.01 0.02 1.01 1.001.01 0.03
Fuhrman grade
Grade 12 64
Grade 34 63 1.05 0.671.64 0.83
Lymph node involvement
N0 118
N1 14 4.66 2.488.75 <0.001 3.47 1.766.94 <0.001
Metastatic state
M0 107
M1 25 3.11 1.865.21 <0.001 2.49 1.364.58 0.003
T-stage
stage T1T2 58
stage T3T4 74 1.78 1.122.84 0.01 1.12 0.661.90 0.68
Analyzed with the Cox hazard regression model.
HR: hazard ratio; CI: confidence interval; N0: no lymph node involvement; N1: positive lymph node involvement; M0: no metastasis; M1:metastatic lesions;
T-stage: tumour stage.
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Discussion
Our results show that S-TATI concentrations significantly pre-
dict OS and CSS both as dichotomized and as continuous
variables. Continuous variables are essential when evaluating
and implementing new biomarkers, as they are less vulner-
able to statistical errors [22]. However, dichotomized varia-
bles, with clear cut-off thresholds, are useful for clinicians
when planning the follow-up scheme. To the best of our
knowledge this is the first study in which S-TATI has been
evaluated as a continuous variable during follow-up of RCC
patients in a post-nephrectomy setting.
Previous studies have shown that preoperative S-TATI
with a cut-off value of 16 mg/l predicted OS and CSS in RCC,
although only in UVA [8]. In line with previous studies, the
preoperative S-TATI in our study population was also a sig-
nificant prognostic factor with a cut-off point of 16 mg/l.
The carcinogenic pathways that affect TATI expression in
RCC are not well understood. S-TATI concentrations increase
with increasing stage of RCC [8]. As a continuous variable,
the preoperative S-TATI concentration also correlated with
TNM-stage and with the preoperative C-reactive protein con-
centration, whereas postoperative S-TATI did not. S-TATI
should be considered as an addition to established prognos-
tic factors. Postoperative S-TATI may improve postoperative
prognostication beyond traditional factors for patients with
localized RCC.
Postoperatively, S-TATI concentrations may become ele-
vated due to surgical stress or inflammation as S-TATI may
behave as an acute phase reactant in severe inflammatory
disease and trauma [23]. However, S-TATI has been shown to
normalize within 2 weeks after tissue injury [12,13]. TATI, a
6 kDa peptide, is eliminated through the kidneys and conse-
quently serum concentrations are elevated in patients with
markedly impaired renal function. Likewise, our analyses
Table 3. Univariate and multivariate analyses of postoperative S-TATI, other prognostic factors and RCC cancer-specific survival.
UVA MVA
Variable Patients (n) HR 95% CI p HR 95% CI p
Sex
Female 62
Male 70 0.75 0.41 1.40 0.37
Patient age (years) 132 1.01 0.98 1.03 0.69
Postoperative s-TATI as a continuous variable 132 1.01 1.00 1.02 0.004 1.01 1.00 1.02 0.004
Fuhrman grade
Grade 1 2 64
Grade 3 4 63 1.62 0.87 3.05 0.13
Lymph node involvement
N0 118
N1 14 6.42 3.11 13.22 < 0.001 3.15 1.48 6.72 0.003
Metastatic state
M0 107
M1 25 6.24 3.34 11.65 < 0.001 3.09 1.55 6.16 0.001
T-stage
Stage T1 T2 58
Stage T3 T4 74 5.78 2.42 13.82 < 0.001 3.36 1.31 8.64 0.012
Cox regression.
HR: hazard ratio; CI: confidence interval.
Figure 4. Overall survival of 132 patients with renal cell carcinoma by concen-
tration of postoperative s-TATI.
Figure 5. Overall survival of 136 patients with renal cell carcinoma by concen-
tration of preoperative s-TATI.
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confirmed postoperative S-TATI measurements and CKD
grade to be significantly associated. Radical and partial neph-
rectomy are known to impair renal function [24,25] and
improvements in renal function tend to continue past the
first postoperative year [26]. Thus, patients with severely
impaired renal function were excluded from our study and
postoperative serum samples were taken after a minimum of
25 days after the operation to minimize the confounding
effect of impaired kidney function and tissue injury. A previ-
ous study by Lukkonen et al. [9] did not exclude any patients
due to kidney deficiency; however, they tested only pre-
operative S-TATI.
To confirm the effect of kidney dysfunction on the prog-
nostic impact of S-TATI, we tested S-TATI without exclusions
based on renal dysfunction, and postoperative S-TATI was
able to predict CSS significantly in multivariate analysis.
However, post-operative S-TATI could not predict overall sur-
vival. As end-stage renal disease carries a high risk of death
and long-term haemodialysis shortens the life-expectancy
with RCC patients [27], there are several confounding factors
when it comes to overall mortality. With such a limited
patient material, we could not evaluate factors possibly
affecting the overall mortality of ESRD patients. Therefore,
without further studies, we cannot recommend the use of
postoperative S-TATI as a prognostic marker for ESRD
patients. Based on current knowledge, postoperative S-TATI
can be used as an additional prognostic marker for patients
with CKD grade 1–3.
We expected elevated concentrations of TATI after surgery
of N0M0 tumours to indicate the presence of an otherwise
undetectable tumour and be a prognosticator for early recur-
rence. However, postoperative TATI with a cut-off limit of
16mg/l did not significantly predict the recurrence in patients
operated on for N0M0 disease in the present study. No firm
conclusions regarding recurrence can be drawn from this
subset of patients because of the limited sample size of
recurring patients (n¼ 26) in our study.
There is a growing need for biomarkers that, in combin-
ation with clinico-pathological risk algorithms, can discrimin-
ate between indolent and aggressive renal cell cancers.
There are limitations with the use of current risk algorithms.
No serum biomarker is currently available for postoperative
follow-up of RCC patients. Biomarker-based postoperative
monitoring is continuously studied using various markers
[28,29]. A clinically applicable biomarker would optimally be
easy to measure and inexpensive to use. Our results indicate
that S-TATI might have the potential to be integrated in cur-
rently used postoperative follow-up protocols. In the future,
TATI has been suggested to have the potential to become a
target molecule for cancer therapy, emphasizing its import-
ance also in RCC [30].
Limitations of this study include a relatively small sample
size that yielded a small number of ccRCC patients with
tumour recurrence. We did not perform serial S-TATI meas-
urements and postoperative S-TATI samples were not taken
at the same fixed time-point after surgery, which limits the
interpretation of our findings. If the results of this study can
be validated, then the postoperative concentrations of S-TATI
might facilitate detection of otherwise non-detectable
residual tumour tissue and also to predict both recurrence
and mortality in RCC patients without severe kidney dysfunc-
tion. In the future, comparison between S-TATI and other
cost-effective and easy-to-use prognostic markers predicting
survival and recurrence, such as neutrophil-to-lymphocyte
ratio [31] or platelet-to-lymphocyte ratio [31], would be of
utmost interest.
Conclusions
Our results suggest that postoperative S-TATI could be a use-
ful prognostic marker in RCC either as an independent bio-
marker or when used in combination with clinical and
histological parameters.
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